Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vicore Pharma Holding ABVCRE +4.17%13 Net Cash per Share is $3.10 as of Jun. 2026, which is 28% below its 10-year median of 4.31. GuruFocus rates VCRE with a GF Score™ of 13/100. The stock has 2 warning signs investors should review. Among 757 Biotechnology companies, Vicore Pharma Holding AB ranks better than 66.45% on this metric.
Vicore Pharma Holding AB (NAS:VCRE) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Vicore Pharma Holding AB Net Cash per Share Related Terms
Vicore Pharma Holding AB Net Cash per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VCRE vs VRTX, REGN, RVMD: Net Cash per Share Comparison
For the Biotechnology subindustry, Vicore Pharma Holding AB's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vicore Pharma Holding AB Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Vicore Pharma Holding AB's Price-to-Net-Cash falls into.
Vicore Pharma Holding AB Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Vicore Pharma Holding AB's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vicore Pharma Holding AB (VCRE) has a Net Cash per Share of $3.10 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Vicore Pharma Holding AB and its competitors. This is 28% below median its historical median of 4.31. Over the past decade, Vicore Pharma Holding AB's Net Cash per Share has ranged from 1.68 to 114.32. According to the industry distribution chart, Vicore Pharma Holding AB ranks #254 out of 757 companies in the Biotechnology industry, placing it in the top 33.6%.
Is Vicore Pharma Holding AB's Net Cash per Share too high?
Vicore Pharma Holding AB's current Net Cash per Share of $3.10 is 28% below median its 10-year median of 4.31. Over the past 10 years, this metric has ranged from a low of 1.68 to a high of 114.32. The Biotechnology industry median Net Cash per Share is 5.17. Vicore Pharma Holding AB's value of $3.10 is 40% below this industry median. Based on the distribution chart, Vicore Pharma Holding AB ranks #254 out of 757 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vicore Pharma Holding AB has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Vicore Pharma Holding AB's Net Cash per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vicore Pharma Holding AB ranks #254 out of 757 companies for Net Cash per Share. This puts Vicore Pharma Holding AB in the upper half of its industry. The industry median Net Cash per Share is 5.17. Vicore Pharma Holding AB's value of $3.10 is 40% below this benchmark. Historically, Vicore Pharma Holding AB's own Net Cash per Share has ranged from 1.68 to 114.32 over the past decade. While the company's 10-year median is 4.31 vs. the industry median of 5.17, Vicore Pharma Holding AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.17, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vicore Pharma Holding AB's current Net Cash per Share of $3.10 is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Vicore Pharma Holding AB and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vicore Pharma Holding AB's current Net Cash per Share is $3.10, which is 28% below median its own 10-year median of 4.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vicore Pharma Holding AB stock overvalued right now?
Vicore Pharma Holding AB (VCRE) has a current Net Cash per Share of $3.10. The current Net Cash per Share is $3.10, which is 28% below median its 10-year median of 4.31 and 40% below the Biotechnology industry median of 5.17. Vicore Pharma Holding AB's overall GF Score™ is 13/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Vicore Pharma Holding AB (VCRE), the current Net Cash per Share is $3.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
13GF Score
Get the complete analysis for VCRE
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VCRE has been successfully added to your 
